Pharming says it's closing in on Rhucin approval

Pharming says that the positive interim results it has received from a study of Rhucin is blazing the way to EMEA approval. The Amsterdam-based developer says it expects EMEA approval in the fourth quarter and should be able to launch the drug, which treats hereditary angioedema, in early '08. The company says it is also just weeks away from completing a U.S. study, and should be able to submit data from that trial for FDA approval. Pharming expects the therapy should garner up to €600 million a year in both the U.S. and Europe. The drug developer's shares jumped about 25 percent on the news.

- see Pharming's release
- and here's the report from ABC Money

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.